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Mycoprotein consumption has been shown to improve acute postprandial glycaemic control 2 
and decrease circulating cholesterol concentrations. We investigated the impact of 3 
incorporating mycoprotein into  the diet on insulin sensitivity (IS), glycaemic control and 4 
plasma lipoprotein composition. Twenty healthy adults participated in a randomised, parallel-5 
group trial in which they consumed a 7 d fully-controlled diet where lunch and dinner contained 6 
either meat/fish (CON) or mycoprotein (MYC) as the primary source of dietary protein. Oral 7 
glucose tolerance tests were performed pre- and post- intervention, and 24h continuous blood 8 
glucose monitoring was applied throughout. Fasting plasma samples were obtained pre- and 9 
post- intervention and were analysed using quantitative, targeted NMR-based metabonomics. 10 
There were no changes within or between groups in blood glucose or serum insulin responses, 11 
nor in IS (Cederholm; 51±3 to 51±3 and 54±3 to 53±3 mg.L2/mmol.mU.min in CON and MYC, 12 
respectively; P<0.05) or 24 h glycaemic profiles. No differences between groups were found 13 
for 171 of the 224 metabonomic targets. Forty five lipid concentrations of different lipoprotein 14 
fractions (VLDL, LDL, IDL and HDL) remained unchanged in CON but showed a coordinated 15 
decrease (7-27 %; all P<0.05) in MYC. Total plasma cholesterol, free-C, LDL-C, HDL2-C, 16 
DHA and omega-3 fatty acids decreased to a larger degree in MYC (14-19 %) compared with 17 
CON (3-11 %; P<0.05). Substituting meat/fish for mycoprotein twice-daily for one week did 18 
not modulate whole-body IS or glycaemic control but resulted in changes to plasma lipid 19 
composition; the latter primarily consisting of a coordinated reduction in circulating cholesterol 20 




Growing evidence suggests dietary protein consumption above the current reference daily 23 
allowances (i.e. 0.75-0.8 g/kg/day in the UK and the USA(1; 2)) may confer metabolic benefits 24 
relating to healthy ageing and weight management, such as improved glycaemic control(3; 4; 5; 25 
6; 7; 8; 9). In parallel, increasing data are accumulating concerning the environmental cost of 26 
intensive animal-derived dietary protein production(10), resulting in shifting social attitudes and 27 
government initiatives towards more sustainable sources. As a consequence, the efficacy of 28 
non-animal derived, sustainably produced dietary proteins to support glycaemic control and 29 
metabolic health is a pressing research focus. 30 
Mycoprotein is a low-energy food source, rich in protein and fibre, derived from the continuous 31 
cultivation of the fungus Fusarium venenatum(11). For the production of an equivalent amount 32 
of edible protein, mycoprotein requires less water and land usage, and has a reduced carbon 33 
footprint when compared with meat and dairy(12; 13; 14), positioning it as a sustainable alternative 34 
protein source.  35 
Previous work has shown that the ingestion of a single mycoprotein-rich meal in combination 36 
with an oral glucose tolerance test results in reduced postprandial glycaemia and insulinaemia 37 
compared with isonitrogenous and isoenergetic control meals(16; 17). The careful matching of 38 
nutritional conditions in these studies suggests that either mycoprotein was delaying intestinal 39 
glucose absorption or improving postprandial (peripheral) glucose uptake, with either effect 40 
plausibly linked to the amino acid composition or fibre content (and type) contained within 41 
mycoprotein. We have recently shown that protein digestion and amino acid absorption 42 
following mycoprotein ingestion is sustained during the acute postprandial period, highlighting 43 
the potential of this alternative protein source to modulate glycaemic control(15). However, 44 
whether these findings translate to habitual mycoprotein consumption improving 45 
physiologically relevant, longer-term changes in insulin sensitivity and/or glycaemic control 46 
has not been investigated.  47 
Studies that have investigated the incorporation of mycoprotein into the habitual diet (20-60 g 48 
dry weight per day for 3-8 weeks using either fully-controlled or supplemented free living 49 
nutritional interventions) have reliably shown a 0.4–0.8 mmol/L lowering of blood cholesterol 50 
concentrations and improvements in LDL:HDL ratios in healthy and hypercholesterolemic 51 
individuals(18; 19). These studies designed the nutritional interventions in an energy- and 52 
macronutrient- matched manner, and therefore the higher fibre content of the mycoprotein 53 
conditions is likely the causative factor (27-39 g per day in the mycoprotein based diets vs 25-54 
27 g per day in the control diets).  55 
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In the present study, we applied a one week fully controlled dietary intervention in healthy 56 
young adults where the major source of dietary protein at lunch and dinner was obtained from 57 
meat and fish (control group; CON) or from mycoprotein (intervention group; MYC) with 58 
energy and macronutrient (except fibre) content of the diets matched. We hypothesised that 59 
one week of mycoprotein consumption would improve whole-body insulin sensitivity and 24 60 
h free living glycaemic control. We also applied a novel, targeted Nuclear Magnetic Resonance 61 
(NMR) based quantitative metabonomics approach of 224 relevant metabolites that has been 62 
epidemiologically validated as a biomarker of insulin sensitivity(20) and would allow further 63 
insight as to the impact upon metabolic profile of mycoprotein consumption.  64 
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Subjects and Methods 65 
Participants and medical screening 66 
Twenty healthy, recreationally active, young adults (age: 24±1 y; BMI: 23±1 kg/m2; male = 8 67 
and female = 12) participated in the present study. Subjects’ characteristics are presented in 68 
Table 1. Prior to participating, each subject attended a screening visit to ensure eligibility. 69 
Blood pressure, body mass, height and body composition (determined by air displacement 70 
plethysmography; Bodpod; Life Measurement, Inc., Concord, CA, USA) were measured at 71 
screening. The participants also completed a general health questionnaire and the International 72 
Physical Activity Questionnaire (IPAQ)(21). Vegetarians, vegans, smokers, and participants 73 
taking regular medication or suffering from chronic diseases were excluded. Participants 74 
regularly consuming >2.5 or <0.8 g/kg of protein per day were also excluded. Participants 75 
included were recreationally active (partook in regular exercise or sport at a non-competitive 76 
level, two to five days a week), were normotensive, and had a BMI between 18.5 and 30 kg/m2. 77 
Half of the female participants (6/12) were taking hormonal contraceptives. When this was not 78 
the case, female participants were tested (and their habitual data collected) during the follicular 79 
phase of their menstrual cycle, to control for cycle variations in glucose and insulin 80 
responses(22). All participants were informed of the study’s purposes, procedures and risks, and 81 
provided written informed consent. The study was conducted at the Nutritional Physiology 82 
Research Unit, Department of Sport and Health Sciences, St. Lukes campus, University of 83 
Exeter, between January and December of 2017, and it was approved by the University of 84 
Exeter’s Sport and Health Sciences Ethics Committee (Ref No: 161026/B/07) in accordance 85 
with the Declaration of Helsinki and registered at ClinicalTrials.gov (NCT02984358). 86 
 87 
Experimental Protocol 88 
The present study was a randomised, controlled, parallel design trial, with participants being 89 
randomly allocated into one of two dietary interventions which differed with respect to the 90 
primary source of dietary protein consumed: meat/fish derived dietary protein (CON; n=10) or 91 
mycoprotein (MYC; n=10). Participants were allocated sequential numbers at the time of 92 
screening which were then used as the only identifiable characteristic for all documents 93 
containing participant information, and were randomised into groups using an online 94 
randomiser (http://www.randomization.com/), with stratification by sex. Figure 1 shows an 95 
overview of the study design. All subjects underwent a period of habitual data collection as 96 




Habitual data collection 99 
Habitual data collection took place either during the 2 weeks before (CON; n=7, MYC; n=7) 100 
or between 2 and 8 weeks following (CON; n=3, MYC; n=3) the experimental period. Subjects 101 
were asked to complete a 3-day food diary to assess their habitual dietary intake, following 102 
consultation with a qualified nutritionist concerning how to complete this in as much detail as 103 
possible. All food and drink consumed were recorded for three consecutive days, including two 104 
weekdays and one weekend day. The diaries were analysed for energy and macronutrient 105 
content using Nutritics (Nutritics Professional Nutritional Analysis Software, Swords, Dublin, 106 
Ireland). Participants wore a GENEActiv Original accelerometer (ActivInsights, Kimbolton, 107 
UK), a wrist-worn device to measure daily physical activity by intensity, on their non-dominant 108 
wrist, for 5 consecutive days (including both week and weekend days). Physical activity data 109 
from the GENEActiv monitors were processed using GENEActiv excel macros. The 5 days of 110 
habitual physical activity data were compiled into an individual average for each participant 111 
and the same was done for the 7 days of the intervention. Glucose sensors were placed 112 
subcutaneously at the side of the abdomen and connected to a continuous glucose monitoring 113 
system (CGMS; Dexcom G4 Platinum, San Diego, California, USA) to measure interstitial 114 
glucose concentrations (calibrated to blood glucose concentrations measured via finger prick 4 115 
times per day) every 5 minutes for the same 5 days as those where accelerometry data were 116 
collected. During all habitual data collections, participants were instructed not to change their 117 
normal routines. 118 
 119 
Experimental test days  120 
Participants reported to the laboratory at ~08.00 on day 0 (prior to starting the dietary 121 
intervention) and on day 8 (the morning following the intervention) after an overnight fast and 122 
refraining from intense exercise and alcohol consumption for at least 24 hours, to undertake 123 
two identical experimental test days. A cannula was placed retrogradely in a dorsal hand vein 124 
and the hand was then placed in a heated box (55ºC) for arterialised venous blood sampling 125 
before a fasted arterialised-venous blood sample was collected(23). Fasted measurements of 126 
oxygen consumption (V̇O2) and carbon dioxide production (V̇CO2) were collected using a 127 
facemask and the Metamax 3B (MM3B) portable indirect calorimetry system (Cortex, Leipzig, 128 
Germany) for 30 minutes. Carbohydrate and fat oxidation rates, as well as resting metabolic 129 
rate (RMR), were calculated using the Frayn equations(24). Subsequently, an oral glucose 130 
tolerance test (OGTT) was performed. Briefly, participants ingested 75 g glucose (dextrose, 131 
BulkPowders, Colchester, United Kingdom) dissolved in 350 mL water in 5 minutes or less 132 
8 
 
(with the exact time being recorded for each participant in the first visit and replicated on the 133 
last test day). Arterialised venous blood samples were then collected for a 2 h period at 15 min 134 
intervals for the measurement of glucose and insulin concentrations and the subsequent 135 
calculation of glucose tolerance and insulin sensitivity. Indirect calorimetry was performed 136 
throughout the OGTT period with the exception of the first 15 minutes following glucose 137 
ingestion.  138 
 139 
Dietary intervention 140 
Basal metabolic rate (BMR) was estimated using the Henry equations based on age, gender, 141 
and weight(25). The IPAQ was used to calculate a physical activity level (PAL) factor(26). 142 
Individual energy requirements were then calculated by multiplying the participant’s BMR and 143 
PAL. Thereafter, an individual 7-day meal plan was designed for each participant with all food 144 
prepared, weighed and packaged in-house in the department’s research kitchen facility. 145 
Nutritional information for the two diets is provided in Table 2. Subjects consumed a diet 146 
containing 1.2 g of protein per kg of body weight per day (in order to reflect an average UK 147 
diet(27)), with 30% of their energy being provided by fat and the remainder from carbohydrates 148 
(~50–55%; variation due to different energy requirements and the clamping of protein intake). 149 
The meals were identical between the two groups, aside from meat or fish providing the 150 
primary protein source in lunches and dinners for the CON group (n=10) and this being 151 
replaced by Quorn Foods™ products (to provide the required amount of mycoprotein) in the 152 
MYC group (n=10). The CON group consumed meals based on chicken, ham, beef, tuna and 153 
salmon. In the MYC group, this was substituted for Quorn chicken pieces, Quorn mince, Quorn 154 
fillets and Quorn roast chicken slices. An additional line of interest was the impact of the 155 
mycoprotein diet on plasma short chain fatty acid concentrations. Acetate, for example, can be 156 
produced from gut microbial fermentation of dietary fibre (with the mycoprotein diet being 157 
high in dietary fibre) but also from hepatic metabolism of alcohol(28). To isolate the impact of 158 
the diet, we therefore chose not to provide any alcohol during the intervention, and required 159 
participants to abstain from alcohol for 24 h prior the start of the intervention. All participants 160 
reported adhering to these guidelines. A document and diary detailing the plan were provided 161 
to the subjects in order to track compliance to the dietary intervention, log meal times and 162 
provide recipe information/instructions. While no formal data concerning tolerability and 163 
dietary preferences/liking were collected during the intervention, subjects informally reported 164 
no particular disliking of any foods, nor any adverse events (e.g. GI, nausea etc.), and 165 
compliance and feedback were similar across groups. 166 
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Participants were required to visit the laboratory at ~08.00 in the fasted state on days 2, 4 and 167 
6 where body mass was measured wearing light clothing (seca 703 column scale, seca, 168 
Germany) and the next two days of food were provided. In these interim visits, the researchers 169 
discussed with the participants any questions or issues that may have arisen, and in the event 170 
of any substantial weight change (>0.5 kg, with the same upward or downward trend on two 171 
consecutive visits) the energy content of the next two days was adjusted. The GENEActiv 172 
accelerometer was worn for the duration of the one-week intervention and on day 2 a glucose 173 
sensor was placed and the CGMS connected to collect continuous glucose data for the last 5 174 
days of the intervention. Following the one-week intervention (i.e. day 8), participants were 175 
required to repeat the experimental test day where a further OGTT was performed as described 176 
above. 177 
 178 
Plasma and serum collection and analyses 179 
One mL of each blood sample was collected into FX blood collection tubes (Becton Dickinson, 180 
Franklin Lakes, New Jersey, USA) containing powdered sodium fluoride and potassium 181 
oxalate, and glucose was immediately analysed using the YSI 2300 STAT PLUS Biochemistry 182 
Analyser (YSI, Yellow Springs, Ohio, USA). Four mL of blood were collected into LH (lithium 183 
heparin) plasma tubes (Becton Dickinson) and immediately centrifuged. The remaining 4 mL 184 
of each blood sample were collected into SST tubes (containing spray-coated silica and a 185 
polymer gel for serum separation; Becton Dickinson) and left at room temperature for at least 186 
30 minutes. All tubes were centrifuged at 4º C and 4000 RPM, and aliquoted (one aliquot 187 
designated for each of the below analyses) plasma and serum were stored at -80º C. 188 
One aliquot of each postabsorptive serum sample was transported to the Clinical Chemistry 189 
department of the Royal Devon & Exeter NHS Foundation Trust and analysed for uric acid 190 
concentrations using the Roche Cobas 702 module of the Cobas 8000 analyser (Roche, Basel, 191 
Switzerland) and Roche Uric Acid Kits (Cobas; UA2). Insulin concentrations were analysed in 192 
serum samples using DRG ELISA kits (DRG International, Springfield, New Jersey, USA). 193 
IL-6 concentrations were measured in plasma samples using Quantikine ELISA kits (R&D 194 
Systems, Minneapolis, Minnesota, USA).  195 
Plasma samples were also sent to the MRC Integrative Epidemiology Unit at the University of 196 
Bristol for metabolomics analysis by nuclear magnetic resonance (NMR) spectroscopy. NMR 197 
spectroscopy and mass spectrometry (MS) are the key technologies in the metabolomics field, 198 
however, MS cannot analyse lipoproteins, making NMR currently the only high-throughput 199 
methodology capable of quantifying these metabolites in a cost-effective manner(29). 200 
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Biomarker concentrations quantified by this NMR approach have been shown to be highly 201 
consistent with concentrations obtained from standardised clinical chemistry analyses(30). For 202 
a detailed description of the experimental protocol, including sample preparation and NMR 203 
spectroscopy please see references(29; 30; 31). The data were then processed using the Nightingale 204 
Health’s NMR-based blood biomarker analysis platform, which provides 224 quantified 205 
metabolomic measures per sample (142 primary concentrations plus 82 selected ratios and 206 
molecule diameters), including the lipid concentrations and composition of 14 lipoprotein 207 
subclasses, fatty acids, amino acids, glycolysis-related measures and ketone bodies. This 208 
approach has previously been used to establish large scale and cross-sectional plasma lipid 209 
metabolic profiles of more metabolically compromised populations compared with healthy 210 
controls(32; 33) but its use in human nutrition trials is a novel application as, to date, NMR 211 
spectroscopy has rarely been applied to investigate changes in response to nutritional 212 
interventions(34). 213 
 214 
Insulin sensitivity 215 
Five different insulin sensitivity indices(35; 36; 37; 38; 39), all validated against the hyperinsulinemic 216 
euglycemic clamp technique, were calculated pre and post intervention using the blood glucose 217 
and serum insulin concentrations measured in the fasting state and during the OGTTs. The 218 
homeostatic model assessment (HOMA-IR) is calculated from solely fasting concentrations of 219 
glucose and insulin and has been shown to provide a reasonable estimate of hepatic insulin 220 
sensitivity(35). The Matsuda index uses OGTT glucose and insulin concentrations, as well as 221 
their corresponding fasting values, and represents a combined estimate of both hepatic and 222 
peripheral tissue sensitivity(37). The Cederholm, OGIS and GUTT indices focus mainly on 223 
peripheral insulin sensitivity and muscular glucose uptake by measuring OGTT glucose 224 
clearance(36; 38; 39). 225 
 226 
Continuous glucose monitoring system (CGMS) 227 
The Dexcom G4 Platinum CGMS sensor was placed in the participants’ abdominal 228 
subcutaneous fat, using a dedicated applicator. A transmitter was then attached to the sensor 229 
and glucose data, collected every 5 minutes, was automatically sent to a receiver. The 230 
participants were instructed to carry the receiver at all times and to calibrate the monitor 4 times 231 
a day at regular intervals by pricking their fingers with disposable lancets and using Contour 232 
Next blood glucose meters (Bayer, Leverkusen, Germany). Data from the days when the sensor 233 
was inserted and removed were excluded (i.e. days 2 and 8). Days with data for fewer than 234 
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70% of the total timepoints were also excluded. The remaining data were analysed for 235 
glycaemic control (24 h average glucose, glucose area under the curve (AUC) and two-hour 236 
postprandial glucose) and for glycaemic variability (SD, CONGA1 and CONGA2). To 237 
calculate the CONGA1 and CONGA2 indices, the SD of the differences between each glucose 238 
concentration reading and the reading obtained 1 (CONGA1) or 2 (CONGA2) hours prior was 239 
determined(40). 240 
 241 
Statistical analyses 242 
A power analysis based on the assumption of a 12% increase in the Matsuda Index with 243 
mycoprotein consumption (calculated based on previous research(16)) was performed and 244 
determined that 8 participants were needed in each group to provide a power of 80% and a 95% 245 
CI. Ten participants per group were recruited to account for a potential 20% dropout rate. 246 
Recruitment and testing was ended once the trial was fully recruited according to the a priori 247 
power calculation. 248 
Participant baseline characteristics, dietary intake, and physical activity data were analysed 249 
using multiple unpaired t-tests. The two groups were compared, for most parameters, using a 250 
two-way ANOVA with repeated measures [RM] (with condition and time [RM] as factors). 251 
Bonferroni post hoc tests were performed in the event of significant main effects to detect 252 
individual differences. Blood glucose and serum insulin concentrations during the pre- and 253 
post- intervention OGTTs were analysed with three-way ANOVAs (condition, time and test 254 
day as factors). Additionally, for the aforementioned parameters, incremental Area Under the 255 
Curves (iAUC) were calculated and a one-way ANOVA was performed to detect any 256 
significant effect of treatment. Carbohydrate and fat oxidation data were averaged as fasting 257 
and fed responses and analysed with three-way ANOVAs (condition, fasted or fed state, and 258 
test day as factors). For the NMR metabolomics measures, a % change (Δ) from pre- to post- 259 
intervention was calculated for each of the 224 metabolites for each participant. The measures 260 
were divided into three groups (concentrations, ratios and dimensions) and analysed using 261 
multiple t-tests for the dimension measures (n = 3) and using Significant Analysis of 262 
Microarrays (SAM) for the concentration and ratio measures (n = 142 and n = 79, respectively). 263 
A heat-map was designed for the significant metabolites and these were organised into clusters. 264 
As an internal validation, a Bland-Altman plot and a Pearson correlation were used to analyse 265 
the agreement between the YSI and metabolomics fasting glucose data. Missing data were 266 
handled using imputation in a linear interpolation manner. Statistical significance was set at 267 
P<0.05. For the SAM analysis, the delta (tuning parameter which determined the False 268 
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Discovery Rate (FDR) threshold) was set at 1 for the analysis of metabolomics ratios, resulting 269 
in a FDR of 0.131 and at 0.8 for metabolite concentrations, resulting in a FDR of 0.095. A FDR 270 
of 0.1 was set for metabolite dimensions analysis. NMR metabolomics calculations were 271 
carried out in MetaboAnalyst 4.0 (Wishart Research Group, University of Alberta, Edmonton, 272 
Alberta, Canada). All other calculations were performed using GraphPad Prism version 7.0 273 




Nutritional intervention 276 
Body mass was not different between habitual testing and at the outset of the intervention in 277 
either group (from 69±4 to 70±4 in CON and 69±6 to 70±6 kg in MYC; P>0.05), nor did body 278 
mass change during the intervention in either group (70±4 and 70±6 kg post intervention in 279 
CON and MYC, respectively; P>0.05) indicating participants remained in energy balance 280 
throughout the entirety of the study period in both groups. 281 
The nutritional content of the prescribed diets, the actual food consumed during the 282 
intervention according to food logs, and participants’ habitual diets are summarised in Table 283 
2. Prescribed diets and actual food consumed did not differ in any parameter, and so all other 284 
comparisons were made using the habitual and actual intervention diets only. There were no 285 
significant differences in the energy and fat intakes between the groups’ habitual diets (both 286 
P>0.05) nor did these parameters change between habitual intake and during the intervention 287 
in either group (all P>0.05). Additionally there were no significant differences in the 288 
carbohydrate and protein intakes between the groups’ habitual diets nor between the groups’ 289 
intervention diets (all P>0.05), but there was a reduction in protein intake and an increase in 290 
carbohydrate intake from their habitual diets to the intervention in both groups (time effect 291 
P<0.05). Although fibre intake was not different between groups (group effect; P>0.05), 292 
significant time and interaction effects were detected (P<0.05), such that fibre intake increased 293 
by 31±2 % in the MYC group only (P<0.05). The MYC group consumed 215±16 g of Quorn 294 
products daily, corresponding to 181±13 g wet weight (45±3 g dry weight) of mycoprotein per 295 
day. In the CON group, 38±1 and 6±1 % of the total protein consumed was provided by meat 296 
and fish, respectively, and in the MYC group, 38±2 % was provided by Quorn products. Dairy 297 
provided 13±1 % of protein in the CON group and 15±2 % in the MYC group (P>0.05), and 298 
32±1 % and 36±2 % of protein in the CON and MYC groups, respectively, came from non-299 
animal sources (not including mycoprotein; P>0.05). The remaining portion of dietary protein 300 
was provided by mixed (plant and animal) sources (e.g. chocolate bars, porridge oat pots, cakes, 301 
etc.).  302 
 303 
Physical activity 304 
Physical activity data are shown in Table 3. Habitual physical activity was not different 305 
between CON and MYC groups when expressed as average daily total activity time, light 306 
activity, moderate activity, vigorous activity, or sedentary time (all P>0.05). None of the 307 
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physical activity parameters changed during the intervention when compared with habitual 308 
levels in either group (all P>0.05).  309 
 310 
Insulin sensitivity 311 
Fasting blood glucose and serum insulin concentrations did not differ between groups at 312 
baseline (both P>0.05) and fasting serum insulin concentrations did not change throughout the 313 
intervention in either group (from 14.8±1.1 to 14.2±1.7 and from 12.3±2.4 to 12.7±1.7 mU.L-1 314 
in CON and MYC, respectively; P>0.05). Pre- and post- intervention fasting blood glucose 315 
concentrations displayed a strong trend for an interaction effect (from 4.41±0.08 to 4.58±0.06 316 
mmol.L-1, and from 4.55±0.11 to 4.47±0.07 mmol.L-1 in CON and MYC, respectively; P=0.05). 317 
Despite this, baseline insulin sensitivity reflected by the HOMA-IR was not different between 318 
groups (2.9±0.2 and 2.7±0.5 in CON and MYC, respectively; P>0.05) and did not change 319 
during the intervention in either group (P>0.05). Blood glucose and serum insulin 320 
concentrations during the two OGTTs performed pre- and post- intervention in the CON and 321 
MYC groups are shown in Figure 2. Both parameters increased with CHO ingestion 322 
(P<0.0001) and peaked between 30 and 45 minutes of the OGTT, at around 8 mmol.L-1 and 323 
100 mU.L-1 for blood glucose and serum insulin concentrations, respectively, with no 324 
differences detected over time or between groups (P>0.05 for interaction and group effects). 325 
Blood glucose iAUC and serum insulin iAUC during the OGTT (displayed in Figure 2) also 326 
did not differ between groups or over time (both P>0.05). Consequently, there were also no 327 
differences between groups at baseline or over the intervention for any of the OGTT derived 328 
calculations of insulin sensitivity (P>0.05 for Cederholm, Matsuda, GUTT and OGIS). Figure 329 
3 displays these four indices and HOMA-IR for the two time points in the two groups. 330 
 331 
Continuous glucose monitoring system (CGMS) 332 
Average daily glucose values were aggregated for the habitual data (5.5±0.1 mmol.L-1 in CON 333 
and 5.4±0.1 mmol.L-1 in MYC) and for each of the intervention days, in the two groups 334 
(5.5±0.1, 5.5±0.2, 5.3±0.2, 5.4±0.1 and 5.4±0.1 mmol.L-1 in CON and 5.7±0.2, 5.5±0.1, 335 
5.4±0.2, 5.3±0.2 and 5.6±0.1 mmol.L-1 in MYC, for days 3 to 7 of the intervention, 336 
respectively). Habitual data demonstrated no differences between groups (P>0.05) and this did 337 
not change throughout the intervention (P>0.05, for time and interaction effects). No 338 
differences were found between groups during the intervention in the average glucose 339 
concentrations in the two-hour postprandial period after the participants’ evening meal 340 
(6.3±0.2, 6.1±0.4, 5.5±0.2, 5.3±0.2 and 5.5±0.2 mmol.L-1 in CON, and 6.0±0.3, 5.9±0.2, 341 
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5.6±0.2, 5.9±0.2 and 6.1±0.2 mmol.L-1 in MYC, for days 3 to 7 of the intervention, respectively; 342 
P>0.05 for time and for interaction effects). There were also no differences in glycaemic 343 
variability between groups, expressed as standard deviation (SD), CONGA1, or CONGA2 (all 344 
P>0.05). 345 
 346 
Indirect calorimetry 347 
There were no differences in RMR between groups before the intervention (1539±114 kcal in 348 
CON and 1692±119 kcal in MYC; P>0.05), and there were no main effects of time, condition 349 
or an interaction effect (all P>0.05). An effect of CHO ingestion was detected for both 350 
carbohydrate (increasing) and fat (decreasing) oxidation rates (P<0.0001). No interaction or 351 
condition effects were found (all P>0.05). The relative contribution of fat and carbohydrate 352 
oxidation to total energy expenditure in both the fasted and fed state are displayed in Figure 4. 353 
 354 
Plasma IL-6 and serum uric acid concentrations 355 
Fasting plasma IL-6 concentrations did not differ between groups at baseline (P>0.05) and did 356 
not change throughout the intervention in either group (from 1.7±0.6 to 1.4±0.6 pg.mL-1, and 357 
from 2.1±0.6 to 1.3±0.4 pg.mL-1 in CON and MYC; P>0.05 for time and interaction effects). 358 
Fasting serum uric acid concentrations were 297±20 µmol.L-1 in the CON group and 260±13 359 
µmol.L-1 in the MYC group at baseline (P>0.05), and remained constant in both groups 360 
throughout the study (main effects of time, condition and interaction; all P>0.05).  361 
 362 
Nuclear magnetic resonance (NMR) based metabolomics 363 
The 224 metabolites measured by NMR metabolomics are listed in Supplementary Table 1. 364 
No differences between groups were found for 171 (93 concentrations, 76 ratios and 2 365 
dimensions) of the quantified targets. Figure 5 and Table 4 summarise the significant changes 366 
found in 53 of the targets (49 concentrations, 3 ratios and 1 dimension). Forty five lipid 367 
concentrations of different lipoprotein fractions (including VLDL, LDL, IDL and HDL) 368 
remained largely unchanged in the CON group (0 – 11 % change) but decreased significantly 369 
in the MYC group (7-27 % decreases; all P<0.05). Plasma free cholesterol concentrations 370 
decreased by 4.00±0.03 % in the CON group (from 0.89±0.06 to 0.86±0.07 mmol.L-1) but by 371 
significantly more (13.99±0.03 %) in the MYC group (from 0.75±0.07 to 0.64±0.06 mmol.L-1; 372 
P<0.05) and, similarly, total (including VLDL, LDL, IDL and HDL) plasma cholesterol 373 
concentrations decreased by 5.23±0.03 % in the CON group (from 3.00±0.19 to 2.86±0.25 374 
mmol.L-1) but to a significantly greater degree (by 14.28±0.03 %) in the MYC group (from 375 
16 
 
2.50±0.26 to 2.12±0.22 mmol.L-1; P<0.05). Plasma LDL cholesterol concentrations decreased 376 
by 2.55±0.07 % in the CON group (from 0.88±0.09 to 0.85±0.11 mmol.L-1) but to a greater 377 
degree, 19.33±0.07 %, in the MYC group (from 0.71±0.13 to 0.56±0.11 mmol.L-1; P<0.05) 378 
and plasma HDL2 decreased by 11.03±0.02 % in the CON group (from 0.91±0.08 to 0.82±0.08 379 
mmol.L-1) but by 18.58±0.03 % in the MYC group (from 0.72±0.07 to 0.58±0.05 mmol.L-1; 380 
P<0.05). DHA and omega 3 fatty acids concentrations decreased by 3.04±0.05 % (from 381 
0.110±0.014 to 0.107±0.015 mmol.L-1) and 2.78±0.05 % (from 0.30±0.02 to 0.29±0.03 382 
mmol.L-1) in the CON group and by 17.26±0.03 % (from 0.085±0.009 to 0.070±0.008 mmol.L-383 
1) and 17.53±0.05 % in the MYC group (from 0.24±0.03 to 0.20±0.02 mmol.L-1), respectively 384 
(both P<0.05). HDL dimensions decreased by 1.26±0.00 % in MYC but only by 0.17±0.00 % 385 
in CON (P<0.05). Interestingly, plasma glucose remained unchanged in the CON group (from 386 
3.8±0.1 to 3.8±0.0 mmol.L-1) but was reduced by 4.49±0.00 % (from 3.8±0.1 to 3.6±0.1 387 
mmol.L-1) in MYC, and plasma acetate concentrations increased by 8.5±0.1 % (from 388 
0.055±0.005 to 0.059±0.006 mmol.L-1) and 43.6±0.1 % (from 0.059±0.005 to 0.083±0.008 389 
mmol.L-1) in CON and MYC, respectively. These changes were not significant using the SAM 390 
multivariate analyses, but were significant when individually analysed (t-tests, P<0.05) which 391 
we deemed appropriate given their lack of involvement in the recognised pathways that the 392 
remainder of the metabolomics SAM analyses took into account. Changes in plasma total 393 
cholesterol, free cholesterol, LDL cholesterol, HDL2 cholesterol, DHA, omega-3 fatty acids, 394 
acetate and glucose concentrations are represented in Figure 6. A Bland-Altman analysis was 395 
performed in order to verify the trend for a decrease in blood glucose concentrations 396 
determined by YSI against the significant change in NMR derived analyses of plasma glucose 397 
in the MYC group. This also served as a verification of the robustness of the NMR based 398 
metabolomics approach. The Bland-Altman plot to analyse the levels of agreement between 399 
the YSI and metabolomics glucose data is represented in Figure 7. There was a strong positive 400 
correlation between the two measurements (r = 0.60; P<0.001; 95% limits of agreement: from 401 




We investigated the impact of substituting meat and fish for mycoprotein as the major source 404 
of dietary protein at lunch and dinner during a fully controlled, energy and macronutrient 405 
balanced one week dietary intervention period on insulin sensitivity, glycaemic control and 406 
plasma lipid composition. We report that the mycoprotein intervention did not change indices 407 
of whole-body insulin sensitivity or 24 h free living glycaemic control. However, the 408 
mycoprotein intervention had a profound impact on the plasma lipidome, inducing changes 409 
generally assumed to be indicative of improvements in long-term cardio-metabolic health. 410 
Earlier studies(16; 17) reported that bolus mycoprotein ingestion improved acute postprandial 411 
glucose handling, but no work had investigated whether this translated to longer term  measures 412 
of metabolic health. We sought to test the hypothesis that chronic (one week), habitual (twice 413 
daily) mycoprotein consumption would improve whole body insulin sensitivity and/or daily 414 
habitual glycaemic control under carefully controlled conditions. We applied a nutritional 415 
intervention with no differences in energy or macronutrient consumption between groups 416 
(except for fibre; see Table 2) to young adults (who were well matched across groups; see Table 417 
1). As a result, in our control group, despite a shift from habitual to controlled dietary 418 
conditions (which can often induce metabolic changes per se(19)), we observed no changes in 419 
any index of insulin sensitivity or glycaemic control. When substituting meat and fish for 420 
mycoprotein as the primary source of dietary protein in lunch and dinner, we also observed no 421 
changes in indices of liver or peripheral insulin sensitivity determined during an oral glucose 422 
tolerance test (Figures 2 and 3). Given the per meal mycoprotein consumption (~90 g wet 423 
weight) was equivalent/in excess of previous work demonstrating bolus mycoprotein 424 
consumption could improve acute glycaemic control(16; 17), this lack of support for our 425 
hypothesis was perhaps surprising. However, those previous studies also indicated the effect 426 
was likely mediated by acute postprandial interactions of mycoprotein with dietary 427 
carbohydrate, rather than an effect on insulin sensitivity per se. Of interest, epidemiological 428 
studies have shown total (postprandial) hyperglycaemia and/or the prevalence of (postprandial) 429 
hyperglycaemic excursions over the day to be better predictors of longer term cardio-metabolic 430 
health(41). As such, to capture any effects of repeated mycoprotein ingestion on cumulative free-431 
living postprandial glycaemic control (which could feasibly be independent of changes in 432 
insulin sensitivity), we applied continuous glucose monitoring throughout the study. However, 433 
whether we looked across the entire day or focussed on postprandial periods only, we did not 434 
observe any impact of the mycoprotein intervention (compared with either habitual conditions 435 
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or the control group). We therefore demonstrate that short-term mycoprotein consumption does 436 
not impact insulin sensitivity or daily blood glucose control, at least in healthy young adults.  437 
It is worth noting that our participants habitually consumed relatively high protein intakes (i.e. 438 
~1.5 g/kg/day) and the intervention therefore represented a ~20% decrease in habitual protein 439 
intake. Since high protein diets have been shown to improve glycaemic control(42) we cannot 440 
discount the possibility that the drop in protein intake obscured any potential changes in insulin 441 
sensitivity or glycaemic control; though, if so, we would expect these effects across both groups 442 
equivalently and our control group also remained unchanged. From a translational perspective, 443 
the protein content of the diet plays a large role in determining free-living energy balance, both 444 
directly via inducing dietary thermogenesis and indirectly based on the leverage of appetite(9). 445 
Given mycoprotein is also a particularly satiating dietary protein source(43; 44; 45), attention 446 
should also be paid when considering mycoprotein (and how much) as a dietary intervention 447 
as to whether over- or under- eating is of primary concern for a particular population. It is 448 
important that future work extends these findings to more (metabolically) compromised 449 
individuals, where such dietary interventions are more likely to induce subtle, but clinically 450 
relevant, alterations in indices of metabolic health. 451 
Our findings are in line with previous work that has reported that nutritionally induced acute 452 
beneficial effects on postprandial glucose handling do not necessarily translate to longer term 453 
benefits on insulin sensitivity(46). Noteworthy, however, is the lowering effect of the 454 
mycoprotein diet on fasting blood glucose concentrations. As a recognised clinical marker of 455 
insulin sensitivity, this suggests mycoprotein consumption may support metabolic health, 456 
although it is difficult to explain why this was observed in the absence of effects on calculated 457 
insulin sensitivity and/or 24 h glucose control. It is possible that mycoprotein consumption 458 
specifically altered glucagon sensitivity (potentially due to mycoprotein’s high fibre 459 
content)(47), or induced early improvements in β-cell function(48), but clearly this warrants 460 
further research. It is crucial such research examines the effects of mycoprotein consumption 461 
during a longer time period and in various (more metabolically compromised) populations, as 462 
these changes may simply have been too subtle to detect in healthy individuals during a 463 
relatively short-term intervention. While our data did not largely support our hypothesis, 464 
incorporating mycoprotein as a sustainably produced alternative to meat clearly does not 465 
negatively impact on metabolic health over a one week period, an important perspective given 466 
the impetus in various populations to reduce animal-derived protein consumption. Indeed no 467 
gastrointestinal or other adverse effects were reported during the mycoprotein intervention, and 468 
the food substitutes were generally well tolerated/liked. While data concerning food 469 
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preferences driving eating behaviour are necessary to evaluate the wider potential/application 470 
of such dietary interventions under free-living conditions, our data indicate mycoprotein 471 
containing products are a practical and feasible simple alternative to animal protein sources. 472 
An existing body of work has demonstrated that 3-8 weeks of mycoprotein consumption 473 
reduces total plasma cholesterol and plasma LDL concentrations thereby resulting in improved 474 
HDL/LDL ratios (a robust marker of beneficial metabolic health outcomes(18; 19; 49)). To shed 475 
further light on this area we applied a novel NMR-based quantitative and targeted 476 
metabonomics approach(50). Strikingly, we found that merely one week of mycoprotein 477 
consumption led to coordinated changes in 53 of our 224 targets (see Table 4 and Figure 6). 478 
Specifically, we report decreases in plasma lipoprotein lipid content and, importantly, in 479 
plasma total, free, LDL and HDL2 cholesterol. However, unlike in previous studies (18; 19), this 480 
reduction in cholesterol was ubiquitous across lipoprotein species, and therefore did not impact 481 
lipoprotein ratios (e.g. LDL/HDL)(51).  482 
We(14) and others(18; 19) have previously argued that the cholesterol lowering effect of 483 
mycoprotein consumption is likely related to the fibre content (or type) it contains (the most 484 
obvious nutritional difference across the diets; 26 vs 34 g daily in CON and MYC, 485 
respectively). While our design (not fibre matched across groups) does not allow us to 486 
disentangle the interesting potential effects of fibre quantity vs type(14), the role of higher fibre 487 
intake in reducing circulating cholesterol concentrations is also in line with epidemiological(52; 488 
53) and intervention(54) studies (2 to 10 g fibre supplementation per day), with these effects also 489 
translating to a reduced risk of coronary heart disease. We therefore provide evidence that an 490 
innocuous and feasible dietary intervention can provide a sufficient increase to dietary fibre 491 
intake to place individuals at the top end of this dose-response effect. Furthermore, we extend 492 
on previous observations(18; 19; 49) by demonstrating how rapidly this effect ensues consequent 493 
to mycoprotein consumption.  494 
The mechanism(s) by which increased fibre intake lowers circulating plasma cholesterol may 495 
be related to large intestinal fermentation of insoluble fibre fractions via the gut microbiota(14; 496 
55). Short-chain fatty acids (SCFAs), such as acetate, propionate and butyrate, are primary 497 
products of fibre fermentation(56). Though SCFAs have been shown to have a range of 498 
metabolic effects(57; 58; 59; 60; 61), of note is the reported effect of (propionate in particular) 499 
reducing hepatic cholesterol synthesis(62). In vitro colonic models have shown mycoprotein’s 500 
fibre (which is composed of approximately two thirds β-glucan and one-third chitin(14)) to be 501 
fermentable to propionate and butyrate, but at the expense of acetate(63), suggesting such end 502 
products could underpin the cholesterol lowering effect. It is, therefore, somewhat surprising 503 
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that we observed a considerable (40%) increase in plasma acetate (Figure 6) following one 504 
week of mycoprotein consumption. However, this is in line with previous work showing the 505 
acute consumption of other dietary fibres leading to increased postprandial serum acetate 506 
concentrations(64), and that fibre (e.g. oat or bran rich diets) induced reductions in circulating 507 
cholesterol are also associated with increases in blood acetate(65). Whether acetate as an in vivo 508 
end product of mycoprotein bacterial fermentation mediated the plasma cholesterol lowering 509 
effect, either by inhibiting cholesterol synthesis, or by other unknown mechanisms (such as 510 
reduced cholesterol absorption or increased peripheral clearance) is not clear, and warrants 511 
future (human) research. 512 
The metabolomics approach also revealed non-cholesterol related changes in the plasma 513 
lipidome. Of note, mycoprotein consumption decreased plasma DHA and omega-3 fatty acid 514 
concentrations (Figure 6), presumably due to a lower dietary load. However, given the reported 515 
variance in plasma levels of these lipids tends to be related to an individual’s last meal, this 516 
may be an acute effect rather than reflective of a ‘deficiency’, particularly over only a one week 517 
period(66). Nevertheless, since omega-3 fatty acids in particular have been linked to various 518 
desirable health outcomes(67) it would be prudent for future dietary interventions that involve 519 
reducing dietary intake of omega-3 (and DHA) lipids to monitor such effects. 520 
In conclusion, the present data show that substituting meat/fish for mycoprotein at lunch and 521 
dinner for one week does not modulate whole-body insulin sensitivity or 24 h free living 522 
(postprandial) glycaemic control, but considerably impacts upon the plasma lipidome. 523 
Mycoprotein represents a sustainable dietary protein source that can be incorporated into the 524 
daily diet without compromising short-term metabolic health and facilitating rapid and possibly 525 
beneficial changes to the plasma lipidome.526 
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Table 1 – Participants’ characteristics  
 CON MYC P value 
Sex 6 F / 4 M 6 F / 4 M - 
Age (y) 24±1 [19 – 31] 24±1 [18 – 31] 0.63 
Height (cm) 174±3 [162 – 188] 171±4 [152 – 189] 0.64 
Body mass (kg) 69±4 [49 – 86] 69±6 [46 – 99] 0.93 
BMI (kg/m2) 23±1 [19 – 28] 23±1 [19 – 30] 0.70 
Body fat (% of body mass) 21±4 [9 – 44] 21±3 [8 – 38] 0.95 
Lean mass (kg) 53±4 [35 – 73] 55±5 [35 – 79] 0.82 
Range of results for each measurement is displayed between [ ]. 
Multiple t-tests were used to compare each characteristic in CON and MYC.  
Abbreviations: CON, control group; MYC, mycoprotein group. 
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Table 2 – Nutritional composition of participants’ habitual diets, of the prescribed intervention diet and of their actual intake during the 
intervention according to the collected logs during the one week intervention 
 
Separate two-way repeated measures ANOVAs were used to compare CON and MYC actual dietary intakes during the intervention with both the habitual diets 
and the prescribed intervention diets.  
Abbreviations: CON, control group; MYC, mycoprotein group. 
* Significantly different from habitual diet (time effect; P<0.05) 
 Habitual dietary intake Prescribed intervention diet Actual intake during intervention 
 CON MYC CON MYC CON MYC 
Energy (MJ/d) 8.9±0.7 10.1±0.6 10.1±0.6 11.0±1.0 10.1±0.6 10.9±0.1 
Energy (kcal/d) 2120±177 2414±150 2422±155 2624±237 2422±152 2598±247 
Protein (g/d) 91±7 107±14 83±5* 84±7* 83±5* 82±7* 
Protein (g/kg body weight) 1.4±0.1 1.6±0.2 1.2±0.0* 1.2±0.0* 1.2±0.0* 1.2±0.0* 
Protein (% total energy) 18.8±1.5 17.6±1.7 13.7±0.4* 13.0±0.5* 13.7±0.4* 12.9±0.6* 
Carbohydrate (g/d) 247±29 260±22 331±22* 355±35* 330±22* 350±37* 
Carbohydrate (% total energy) 41.6±2.5 43.0±2.1 54.5±0.4* 53.9±0.7* 54.4±0.4* 53.4±1.0* 
Fat (g/d) 94±8 99±7 82±5 87±8 82±5 87±8 
Fat (% total energy) 36.8±2.0 37.0±1.7 30.3±0.2* 29.8±0.1* 30.5±0.2* 30.2±0.3* 
Fibre (g/d) 23±2 26±2 26±2 34±2† 26±2 34±2† 
Alcohol (g/d) 8.8±3.6 7.7±3.9 0±0 0±0 0±0 0±0 
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† Significantly different from habitual diet and from CON group (time and interaction effect; P<0.05) 
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Multiple two-way ANOVAs were used to compare the different activity levels in CON and MYC habitually and during the intervention. 




 Habitual Intervention 
 CON MYC CON MYC 
Total activity (mins/day) 241 ± 19 251 ± 34 247 ± 45 295 ± 26 
Light activity (mins/day) 83 ± 4 80 ± 7 85 ± 16 94 ± 9 
Moderate activity (mins/day) 150 ± 15 158 ± 27 154 ± 27 186 ± 18 
Vigorous activity (mins/day) 8 ± 3 12 ± 5 8 ± 3 15 ± 5 
Sedentary (mins/day) 656 ± 24 661 ± 26 659 ± 42 654 ± 34 
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Table 4 – Significant NMR-based metabolomics features identified using either Significant Analysis of 
Microarrays (concentrations and ratios) or t-tests (dimensions) 
Concentrations % Δ change CON SEM % Δ change MYC SEM d.value stdev rawp q.value 
XL-HDL-FC -0.48% 0.05 -25.85% 0.04 -2.4672 0.064471 0.00098592 0.050372 
XL-HDL-C -1.40% 0.04 -23.04% 0.03 -2.3885 0.052223 0.0011972 0.050372 
XL-HDL-CE -1.34% 0.04 -22.11% 0.03 -2.3173 0.051227 0.0016197 0.050372 
XL-HDL-L -1.91% 0.04 -22.18% 0.04 -2.1522 0.055798 0.0033099 0.070958 
XL-HDL-P -1.99% 0.04 -21.94% 0.04 -2.1173 0.055879 0.0038028 0.070958 
XL-HDL-PL -1.84% 0.05 -21.76% 0.04 -1.9285 0.064943 0.006831 0.091044 
L-HDL-FC -9.17% 0.03 -24.54% 0.04 -1.8228 0.045938 0.0088028 0.10266 
L-HDL-C -8.43% 0.02 -21.48% 0.04 -1.5961 0.043399 0.016901 0.12108 
IDL-FC -2.98% 0.04 -18.33% 0.04 -1.585 0.058474 0.017958 0.12108 
L-HDL-L -9.33% 0.02 -20.84% 0.03 -1.5517 0.035824 0.019648 0.12108 
L-HDL-P -9.33% 0.02 -20.62% 0.03 -1.5358 0.035138 0.02007 0.12108 
L-HDL-CE -8.21% 0.02 -20.67% 0.04 -1.5351 0.042784 0.02007 0.12108 
DHA -3.04% 0.05 -17.26% 0.03 -1.4892 0.057088 0.023239 0.12108 
M-LDL-TG -7.08% 0.03 -27.03% 0.09 -1.4817 0.096334 0.024014 0.12108 
IDL-C -2.64% 0.05 -17.21% 0.04 -1.4298 0.063572 0.028732 0.12108 
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M-LDL-P -3.61% 0.06 -25.72% 0.10 -1.4276 0.11648 0.028803 0.12108 
M-LDL-L -3.29% 0.06 -25.32% 0.10 -1.4213 0.11663 0.029577 0.12108 
XL-HDL-TG 0.33% 0.07 -18.45% 0.07 -1.4058 0.09517 0.031056 0.12108 
M-LDL-C -2.02% 0.08 -27.06% 0.12 -1.3926 0.14145 0.032676 0.12108 
L-HDL-PL -10.54% 0.02 -20.19% 0.03 -1.392 0.030936 0.032746 0.12108 
L-LDL-FC -2.12% 0.04 -14.96% 0.03 -1.3761 0.054964 0.034366 0.12108 
L-HDL-TG -3.43% 0.06 -19.38% 0.05 -1.3743 0.077665 0.034507 0.12108 
IDL-CE -2.46% 0.05 -16.74% 0.05 -1.3649 0.066219 0.035634 0.12108 
L-LDL-C -2.71% 0.06 -19.07% 0.06 -1.3617 0.081812 0.035915 0.12108 
IDL-L -2.71% 0.04 -15.08% 0.04 -1.347 0.053468 0.037535 0.12108 
L-LDL-CE -2.94% 0.07 -21.27% 0.07 -1.3285 0.099596 0.03993 0.12108 
FAw3 -2.78% 0.05 -17.53% 0.05 -1.3162 0.073673 0.041338 0.12108 
IDL-P -2.70% 0.04 -14.47% 0.04 -1.309 0.051504 0.04162 0.12108 
S-LDL-L -4.29% 0.06 -24.90% 0.10 -1.3075 0.11925 0.04162 0.12108 
IDL-PL -2.38% 0.03 -13.66% 0.03 -1.306 0.047989 0.041761 0.12108 
S-LDL-P -4.59% 0.06 -25.05% 0.10 -1.3009 0.11887 0.042606 0.12108 
L-LDL-L -3.20% 0.05 -16.65% 0.05 -1.2903 0.065862 0.043592 0.12108 
S-LDL-C -2.61% 0.08 -26.81% 0.13 -1.2792 0.15082 0.045 0.12108 
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L-LDL-P -3.44% 0.05 -16.59% 0.05 -1.2753 0.064748 0.045423 0.12108 
LDL-C -2.55% 0.07 -19.33% 0.07 -1.2438 0.096487 0.050775 0.12622 
M-LDL-FC -2.46% 0.04 -20.02% 0.09 -1.2437 0.10285 0.050775 0.12622 
FreeC -4.00% 0.03 -13.99% 0.03 -1.241 0.042177 0.051408 0.12622 
S-LDL-FC -3.64% 0.05 -20.72% 0.10 -1.1778 0.10661 0.060634 0.14192 
M-LDL-PL -3.03% 0.04 -19.60% 0.10 -1.1769 0.1024 0.060845 0.14192 
XS-VLDL-CE 3.13% 0.04 -7.16% 0.03 -1.1534 0.050838 0.065352 0.14689 
L-LDL-TG -4.61% 0.03 -14.48% 0.03 -1.1497 0.047456 0.066127 0.14689 
LDL-TG -5.97% 0.03 -15.99% 0.04 -1.1321 0.050121 0.070986 0.1535 
S-LDL-TG -8.70% 0.03 -25.25% 0.10 -1.1253 0.10863 0.072394 0.1535 
XS-VLDL-PL -2.38% 0.03 -12.60% 0.04 -1.1087 0.053763 0.076197 0.15798 
XS-VLDL-C 1.26% 0.04 -8.36% 0.03 -1.0857 0.050216 0.081761 0.16583 
S-LDL-PL -4.60% 0.04 -19.57% 0.10 -1.0608 0.10266 0.089507 0.17306 
HDL2-C -11.03% 0.02 -18.58% 0.03 -1.0577 0.03298 0.090563 0.17306 
L-LDL-PL -2.68% 0.04 -11.85% 0.03 -1.0553 0.048557 0.090915 0.17306 
Serum-C -5.23% 0.03 -14.28% 0.03 -1.0515 0.047617 0.092746 0.17306 
         
Ratios % Δ change CON SEM % Δ change MYC SEM d.value stdev rawp q.value 
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XL-HDL-FC_% 1.11% 0.01 -4.74% 0.01 -3.1601 0.018531 0.0060759 0.18544 
L-HDL-FC_% 0.08% 0.01 -5.07% 0.02 -2.9305 0.017575 0.008481 0.18544 
IDL-FC_% -0.38% 0.01 -3.93% 0.01 -2.7984 0.012681 0.010253 0.18544 
         
Dimensions % Δ change CON SEM % Δ change MYC SEM t.stat p.value - log 10 (p) FDR 






Figure 1 Overview of the experimental protocol. 
 
Figure 2 Blood glucose (A, B and C) and serum insulin (D, E and F) concentrations during 
oral glucose tolerance tests (OGTT) on days 0 (A and D) and 8 (B and E) of a fully controlled 
dietary intervention with either a meat-based diet (CON) or a mycoprotein-based diet (MYC). 
OGTT data were analysed using three-way ANOVAs. Incremental area under the curve 
(iAUC) data were analysed using one-way ANOVAs. There was a significant effect of CHO 
ingestion for blood glucose and serum insulin (P<0.0001). No interaction effects or main 
effects of condition or time were found (all P>0.05). For both blood glucose iAUC and serum 
insulin iAUC, no statistically significant main effects of time or condition (both P>0.05), as 
well as no interaction effects (P>0.05) were found. 
 
Figure 3 Insulin sensitivity indices (A: HOMA-IR, B: Cederholm, C: Matsuda, D: OGIS, E: 
GUTT) calculated with the blood glucose and serum insulin concentrations measured fasting 
and during oral glucose tolerance tests (OGTT) pre and post a one week fully controlled dietary 
intervention with either a meat-based diet (CON) or a mycoprotein-based diet (MYC). There 
were no differences between groups at baseline for any of the OGTT calculated insulin 
sensitivity indices (all P>0.05) and no changes resulted from the intervention (time and 
interaction effects; all P>0.05) 
 
 
Figure 4 Relative contribution of fat and carbohydrate oxidation rates to energy expenditure 
calculated via indirect calorimetry using the Frayn equations, in the fasted and CHO fed states, 
pre- and post- a one week fully controlled dietary intervention with either a meat-based diet 
(CON) or a mycoprotein-based diet (MYC). An effect of CHO ingestion was found for both 
carbohydrate and fat oxidation rates (P<0.0001). No interaction or condition effects were found 
(all P>0.05). 
 
Figure 5 Heat map and cluster representation of NMR based metabolomics analyses which 
exhibited significant changes between pre- and post- a one week fully controlled dietary 
intervention with either a meat-based diet (CON) or a mycoprotein-based diet (MYC), 
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calculated by the Δ change for each participant. Participants in CON are represented in red and 
participants in MYC are shown in green.  
 
Figure 6 Selected metabolites from the metabolomics analysis considered of particular 
relevance. Total plasma cholesterol (A), plasma free cholesterol (B), plasma LDL cholesterol 
(C), plasma HDL2 cholesterol (D), plasma DHA (E), plasma omega-3 fatty acids (F), plasma 
acetate (G) and plasma glucose (H) as measured by NMR-based targeted metabolomics pre- 
and post- a one week fully controlled dietary intervention with either a meat-based diet (CON) 
or a mycoprotein-based diet (MYC). NMR metabolomics metabolite concentrations were 
analysed using Significant Analysis of Microarrays (SAM). Total plasma cholesterol, free 
cholesterol, LDL cholesterol, HDL2 cholesterol, DHA and omega-3 fatty acid were decreased 
to a larger degree in the MYC group (14-19% decrease) compared with the CON group (3-11 
% decrease; P<0.05). Plasma glucose remained unchanged in the CON group but was reduced 
by 4.5±0.1 % in MYC and plasma acetate concentrations increased by 8.5±0.1 % and 43.6±0.1 
% in CON and MYC, respectively. The changes in these two variables were significant when 
individually analysed (t-tests, P<0.05) but not when using the SAM multivariate analysis. 
 
Figure 7 Bland-Altman analysis plot for blood glucose concentrations measured by the 
benchtop YSI biochemistry analyser and plasma glucose concentrations measured by NMR 
spectroscopy, representing the consistency of the variant results between the two techniques. 
Measurements for every participant’s sample, pre- and post- a one week fully controlled dietary 
intervention with either a meat-based diet (CON) or a mycoprotein-based diet (MYC) in CON 
and MYC were aggregated. There was a strong positive correlation between the two techniques 
(r = 0.60; P<0.001). 
